Lars Farde

Lars Farde's AcademicInfluence.com Rankings

Lars Farde

Philosophy

#4708

World Rank

#7324

Historical Rank

Logic

#2112

World Rank

#3029

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Lars Farde Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Lars Farde's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. (1992) (1360)
Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. (1986) (854)
Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers (1999) (733)
The correlative triad among aging, dopamine, and cognition: Current status and future prospects (2006) (683)
Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. (1988) (663)
Changes in Cortical Dopamine D1 Receptor Binding Associated with Cognitive Training (2009) (545)
Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: A double-blind PET study of schizophrenic patients (1993) (518)
D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride. (1990) (515)
A PET study of (2000) (515)
Age-related cognitive deficits mediated by changes in the striatal dopamine system. (2000) (469)
Kinetic Analysis of Central [11C]Raclopride Binding to D2-Dopamine Receptors Studied by PET—A Comparison to the Equilibrium Analysis (1989) (463)
Distribution of D1- and D2-Dopamine Receptors, and Dopamine and Its Metabolites in the Human Brain (1994) (399)
Age-related dopamine D2/D3 receptor loss in extrastriatal regions of the human brain (2000) (365)
D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. (1995) (340)
Substituted benzamides as ligands for visualization of dopamine receptor binding in the human brain by positron emission tomography. (1985) (307)
No D2 receptor increase in PET study of schizophrenia. (1987) (297)
Autoradiographic localization of 5-HT1A receptors in the post-mortem human brain using [3H]WAY-100635 and [11C]WAY-100635 (1997) (287)
Transplantation in Parkinson's disease: Two cases of adrenal medullary grafts to the putamen (1987) (274)
Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. (1999) (253)
The role of the striatal dopamine transporter in cognitive aging (2005) (251)
PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease. (1997) (246)
Support for dopaminergic hypoactivity in restless legs syndrome: a PET study on D2-receptor binding. (2006) (230)
Carbon-11-FLB 457: a radioligand for extrastriatal D2 dopamine receptors. (1995) (229)
Reduced midbrain dopamine transporter binding in male adolescents with attention-deficit/hyperactivity disorder: Association between striatal dopamine markers and motor hyperactivity (2005) (228)
D2 dopamine receptors and personality traits (1997) (225)
Cognitive deficits in Huntington's disease are predicted by dopaminergic PET markers and brain volumes. (1997) (223)
Meta-analysis of cognitive performance in drug-naïve patients with schizophrenia (2014) (217)
The serotonin system and spiritual experiences. (2003) (214)
Common brain disorders are associated with heritable patterns of apparent aging of the brain (2019) (213)
Decreased dopamine D2 receptor binding in the anterior cingulate cortex in schizophrenia. (2002) (200)
Clinical Validation of 18F-AZD4694, an Amyloid-β–Specific PET Radioligand (2012) (193)
Imaging of neurotransmitter receptors in the living human brain. (1986) (192)
Advancement in PET quantification using 3D-OP-OSEM point spread function reconstruction with the HRRT (2009) (189)
A PET-study of [11C]FLB 457 binding to extrastriatal D2-dopamine receptors in healthy subjects and antipsychotic drug-treated patients (1997) (188)
Pet study of [11C] β‐CIT binding to monoamine transporters in the monkey and human brain (1994) (181)
Preparation of 11C-labelled SCH 23390 for the in vivo study of dopamine D-1 receptors using positron emission tomography. (1986) (174)
Imaging of [11C]-labelled Ro 15-1788 binding to benzodiazepine receptors in the human brain by positron emission tomography. (1985) (174)
Quantification of [11C]FLB 457 Binding to Extrastriatal Dopamine Receptors in the Human Brain (1999) (173)
Variability in D2‐dopamine receptor density and affinity: A PET study with [11C]raclopride in man (1995) (173)
PET study of D(1) dopamine receptor binding in neuroleptic-naive patients with schizophrenia. (2002) (173)
Limbic reductions of 5-HT1A receptor binding in human temporal lobe epilepsy (2004) (172)
Autoradiographic localization of extrastriatal D2‐dopamine receptors in the human brain using [125I]epidepride (1996) (169)
Comparison of the Transient Equilibrium and Continuous Infusion Method for Quantitative PET Analysis of [11C]Raclopride Binding (1998) (167)
Using positron emission tomography to facilitate CNS drug development. (2006) (159)
Positron Emission Tomography Studies on D2 and 5‐HT2 Receptor Binding in Risperidone‐Treated Schizophrenic Patients (1995) (158)
Antipsychotic Occupancy of Dopamine Receptors in Schizophrenia (2011) (156)
Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson's disease. (2015) (154)
Sex differences in extrastriatal dopamine d(2)-like receptors in the human brain. (2001) (153)
D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics (2004) (151)
PET analysis of human dopamine receptor subtypes using 11C-SCH 23390 and 11C-raclopride (2004) (150)
D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. (1995) (146)
No elevated D2 dopamine receptors in neuroleptic-naive schizophrenic patients revealed by positron emission tomography and [11C]N-methylspiperone (1995) (145)
A PET Study of 5-HT2 and D2 Dopamine Receptor Occupancy Induced by Olanzapine in Healthy Subjects (1997) (138)
Preparation of 11C-labelled Raclopride, a new potent dopamine receptor antagonist: preliminary PET studies of cerebral dopamine receptors in the monkey. (1985) (137)
PET imaging of central 5-HT2A receptors with carbon-11-MDL 100,907. (1998) (134)
Quantitative analyses of carbonyl-carbon-11-WAY-100635 binding to central 5-hydroxytryptamine-1A receptors in man. (1998) (133)
Visualization of the Dopamine Transporter in the Human Brain Postmortem with the New Selective Ligand [125I]PE2I (1999) (129)
Carbon-11-NNC 112: a radioligand for PET examination of striatal and neocortical D1-dopamine receptors. (1998) (128)
Characterization of AZD4694, a novel fluorinated Aβ plaque neuroimaging PET radioligand (2010) (126)
Autoradiographic localisation of D3-dopamine receptors in the human brain using the selective D3-dopamine receptor agonist (+)-[3H]PD 128907 (1996) (126)
Low dopamine d(2) receptor binding in subregions of the thalamus in schizophrenia. (2004) (125)
Decreased thalamic D2/D3 receptor binding in drug-naive patients with schizophrenia: a PET study with [11C]FLB 457. (2003) (121)
AZD2184: a radioligand for sensitive detection of β‐amyloid deposits (2009) (121)
PET evaluation of novel radiofluorinated reboxetine analogs as norepinephrine transporter probes in the monkey brain (2004) (119)
Brain radioligands--state of the art and new trends. (2001) (118)
Extrastriatal dopamine D2 and D3 receptors in early and advanced Parkinson’s disease (2000) (116)
Autoradiographic localization of 5‐HT2A receptors in the human brain using [3H]M100907 and [11C]M100907 (2000) (115)
Performance Evaluation of the Small-Animal nanoScan PET/MRI System (2013) (115)
Effect of amphetamine on dopamine D2 receptor binding in nonhuman primate brain: A comparison of the agonist radioligand [11C]MNPA and antagonist [11C]raclopride (2006) (114)
Chemical brain anatomy in schizophrenia (1995) (114)
Raclopride, a new selective ligand for the dopamine-D2 receptors (1988) (112)
Effect of reserpine‐induced depletion of synaptic dopamine on [11C]Raclopride binding to D2‐dopamine receptors in the monkey brain (1997) (112)
Thinking Outside a Less Intact Box: Thalamic Dopamine D2 Receptor Densities Are Negatively Related to Psychometric Creativity in Healthy Individuals (2010) (111)
Dopamine D1 receptors and age differences in brain activation during working memory (2011) (110)
Serotonin transporter genotype is associated with cognitive performance but not regional 5-HT1A receptor binding in humans. (2009) (110)
Extrastriatal dopamine D2 receptor density and affinity in the human brain measured by 3D PET. (1999) (104)
Extrastriatal dopamine D2 receptor binding modulates intraindividual variability in episodic recognition and executive functioning (2009) (104)
Test–retest reproducibility of [11C]PBR28 binding to TSPO in healthy control subjects (2015) (103)
Dopamine and cognitive functioning: brain imaging findings in Huntington's disease and normal aging. (2001) (102)
Comparison of the In Vitro Receptor Binding Properties of N‐[3H]Methylspiperone and [3H]Raclopride to Rat and Human Brain Membranes (1990) (102)
Potentials and Pitfalls Using High Affinity Radioligands in PET and SPET Determinations on Regional Drug Induced D2 Receptor Occupancy—A Simulation Study Based on Experimental Data (2001) (102)
PET studies with carbon-11 radioligands in neuropsychopharmacological drug development. (2001) (101)
No support for regional selectivity in clozapine-treated patients: a PET study with [(11)C]raclopride and [(11)C]FLB 457. (2001) (101)
Lower levels of the glial cell marker TSPO in drug-naive first-episode psychosis patients as measured using PET and [11C]PBR28 (2017) (100)
Differentiation of extrastriatal dopamine D2 receptor density and affinity in the human brain using PET (2004) (99)
Quantification of 11C-MADAM binding to the serotonin transporter in the human brain. (2005) (99)
The advantage of using positron emission tomography in drug research (1996) (98)
Stereoselective binding of 11C-raclopride in living human brain — a search for extrastriatal central D2-dopamine receptors by PET (2004) (97)
PET examination of [11C]NNC 687 and [11C]NNC 756 as new radioligands for the D1-dopamine receptor (2005) (96)
Individual differences in the proneness to have flow experiences are linked to dopamine D2-receptor availability in the dorsal striatum (2013) (96)
[11C]MDL 100907, a radioligland for selective imaging of 5-HT(2A) receptors with positron emission tomography. (1996) (96)
PET Analysis Indicates Atypical Central Dopamine Receptor Occupancy in Clozapine-Treated Patients (1992) (96)
Saturation analysis of specific 11C Ro 15‐1788 binding to the human neocortex using positron emission tomography (1989) (94)
Time course of D2-dopamine receptor occupancy examined by PET after single oral doses of haloperidol (2005) (93)
Characterisation of the appearance of radioactive metabolites in monkey and human plasma from the 5-HT1A receptor radioligand, [carbonyl-11C]WAY-100635--explanation of high signal contrast in PET and an aid to biomathematical modelling. (1998) (93)
5-HT2 and D2 dopamine receptor occupancy in the living human brain (1993) (91)
Xanomeline: A selective muscarinic agonist for the treatment of Alzheimer's disease (1997) (91)
Lack of apparent antipsychotic effect of the D1-dopamine recepotr antagonist SCH39166 in acutely ill schizophrenic patients (1995) (91)
Measurement of Methylphenidate-Induced Change in Extrastriatal Dopamine Concentration using [11C]FLB 457 PET (2007) (90)
D1-, D2-, and 5-HT2-receptor occupancy in clozapine-treated patients. (1994) (90)
Characterization of the radioactive metabolites of the 5-HT1A receptor radioligand, [O-methyl-11C]WAY-100635, in monkey and human plasma by HPLC: comparison of the behaviour of an identified radioactive metabolite with parent radioligand in monkey using PET. (1996) (88)
Qualitative and quantitative MALDI imaging of the positron emission tomography ligands raclopride (a D2 dopamine antagonist) and SCH 23390 (a D1 dopamine antagonist) in rat brain tissue sections using a solvent-free dry matrix application method. (2011) (88)
Localization of 5-HT1A receptors in the living human brain using [carbonyl-11C]WAY-100635: PET with anatomic standardization technique. (1999) (88)
[11C] beta-CIT, a cocaine analogue. Preparation, autoradiography and preliminary PET investigations. (1993) (87)
Radioligand Disposition and Metabolism — Key Information in Early Drug Development (1995) (87)
Imaging the living human brain: magnetic resonance imaging and positron emission tomography. (1997) (86)
Detection of amyloid in Alzheimer’s disease with positron emission tomography using [11C]AZD2184 (2009) (85)
A preliminary PET evaluation of the new dopamine D2 receptor agonist [11C]MNPA in cynomolgus monkey. (2005) (85)
Kinetic analysis and test-retest variability of the radioligand [11C](R)-PK11195 binding to TSPO in the human brain - a PET study in control subjects (2012) (85)
Workshop on schizophrenia, PET, and dopamine D2 receptors in the human neostriatum. (1988) (84)
Changes in striatal D2‐receptor density following chronic treatment with amphetamine as assessed with pet in nonhuman primates (1999) (84)
The immune response of the human brain to abdominal surgery (2017) (82)
[11C]PE2I: a highly selective radioligand for PET examination of the dopamine transporter in monkey and human brain (2003) (82)
[11C]AZ10419369: A selective 5-HT1B receptor radioligand suitable for positron emission tomography (PET). Characterization in the primate brain (2008) (79)
[11C]β‐CIT‐FE, a radioligand for quantitation of the dopamine transporter in the living brain using positron emission tomography (1996) (79)
Effect of a single dose of escitalopram on serotonin concentration in the non-human and human primate brain. (2013) (77)
Specific in vivo binding to the norepinephrine transporter demonstrated with the PET radioligand, (S,S)-[11C]MeNER. (2003) (77)
Plasma prolactin and central D2 receptor occupancy in antipsychotic drug-treated patients. (1998) (77)
Associations between dopamine D2-receptor binding and cognitive performance indicate functional compartmentalization of the human striatum (2008) (77)
PET-characterization of [carbonyl-11C]WAY-100635 binding to 5-HT1A receptors in the primate brain (1997) (76)
Whole hemisphere autoradiography of the postmortem human brain. (1998) (76)
Iodine-123 labeled nor-β-CIT as a potential tracer for serotonin transporter imaging in the human brain with single-photon emission tomography (1997) (74)
Quantitative Analysis of [11C]AZ10419369 Binding to 5-HT1B Receptors in Human Brain (2011) (74)
PET analysis of central [11 C]raclopride binding in healthy young adults and schizophrenic patients—reliability and age effects (1992) (74)
Positron emission tomography studies on D2 dopamine receptor occupancy and plasma antipsychotic drug levels in man (1995) (74)
Dopamine D2 receptor binding in drug-naïve patients with schizophrenia examined with raclopride-C11 and positron emission tomography (2006) (74)
The role of dopamine systems in cognitive aging (2005) (73)
[11C]MADAM, a new serotonin transporter radioligand characterized in the monkey brain by PET (2005) (71)
Nigrostriatal dopamine transporter availability in early Parkinson's disease (2018) (70)
Regional reductions in serotonin 1A receptor binding in juvenile myoclonic epilepsy. (2005) (70)
[18F]Flumazenil binding to central benzodiazepine receptor studies by PET – Quantitative analysis and comparisons with [11C]flumazenil – (2009) (69)
Reproducibility of [11C]FLB 457 binding in extrastriatal regions (2001) (69)
A comparative PET-study of five carbon-11 or fluorine-18 labelled salicylamides. Preparation and in vitro dopamine D-2 receptor binding. (1991) (68)
Quantitative analyses of regional [11C]PE2I binding to the dopamine transporter in the human brain: a PET study (2006) (68)
Wavelet-Aided Parametric Mapping of Cerebral Dopamine D2 Receptors Using the High Affinity PET Radioligand [11C]FLB 457 (2002) (68)
Measurement of Striatal and Extrastriatal Dopamine Transporter Binding with High-Resolution PET and [11C]PE2I: Quantitative Modeling and Test—Retest Reproducibility (2008) (68)
PET studies on the brain uptake and regional distribution of [11C]vinpocetine in human subjects (2002) (67)
[O-methyl-11C]beta-CIT-FP, a potential radioligand for quantitation of the dopamine transporter: preparation, autoradiography, metabolite studies, and positron emission tomography examinations. (1995) (66)
PET Mapping of Extrastriatal D2-like Dopamine Receptors in the Human Brain Using an Anatomic Standardization Technique and [11C]FLB 457 (1999) (66)
Dopamine D1 receptor associations within and between dopaminergic pathways in younger and elderly adults: links to cognitive performance. (2011) (65)
Atomoxetine occupies the norepinephrine transporter in a dose-dependent fashion: a PET study in nonhuman primate brain using (S,S)-[18F]FMeNER-D2 (2006) (64)
Positron Emission Tomography of in-vivo Binding Characteristics of Atypical Antipsychotic Drugs (1996) (63)
Post-mortem human brain autoradiography of the norepinephrine transporter using (S,S)-[18F]FMeNER-D2 (2005) (62)
Effect of amphetamine on extrastriatal D2 dopamine receptor binding in the primate brain: A PET study (2000) (62)
Age-related reduction in dopamine D1 receptors in the human brain: from late childhood to adulthood, a positron emission tomography study (2010) (62)
A PET study of D1-like dopamine receptor ligand binding (1999) (61)
Simulating Neurocognitive Aging: Effects of a Dopaminergic Antagonist on Brain Activity During Working Memory (2010) (61)
Positron emission tomography finding of a high striatal D2 receptor occupancy in olanzapine-treated patients. (1998) (60)
An open label trial of raclopride in acute schizophrenia. Confirmation of D2-dopamine receptor occupancy by PET (2004) (60)
Preclinical Comparison of the Blood–brain barrier Permeability of Osimertinib with Other EGFR TKIs (2020) (59)
Reduced 5-HT1B receptor binding in the dorsal brain stem after cognitive behavioural therapy of major depressive disorder (2014) (58)
High 5HT2A receptor occupancy in M100907-treated schizophrenic patients (2000) (58)
[18F]β-CIT-FP is superior to [11C]β-CIT-FP for quantitation of the dopamine transporter (1997) (58)
Fenfluramine‐induced serotonin release decreases [11C]AZ10419369 binding to 5‐HT1B‐receptors in the primate brain (2010) (58)
Application of cross-species PET imaging to assess neurotransmitter release in brain (2015) (58)
Human dopamine receptor subtypes—in vitro binding analysis using3H-SCH 23390 and3H-raclopride (2005) (57)
[carbonyl-11C]Desmethyl-WAY-100635 (DWAY) is a potent and selective radioligand for central 5-HT1A receptors in vitro and in vivo (1998) (57)
Pharmacological Characterization ofN,N-Dimethyl-2-(2-amino-4-methylphenyl thio)benzylamine as a Ligand of the Serotonin Transporter with High Affinity and Selectivity (2003) (56)
Genetic Variation in Brain-Derived Neurotrophic Factor Is Associated with Serotonin Transporter but Not Serotonin-1A Receptor Availability in Men (2009) (56)
Delayed normalization of central D2 dopamine receptor availability after discontinuation of haloperidol decanoate. Preliminary findings. (1997) (56)
Association between a promoter dopamine D2 receptor gene variant and the personality trait detachment (2003) (55)
PET analysis of [11C]flumazenil binding to benzodiazepine receptors in chronic alcohol-dependent men and healthy controls (1993) (55)
A comparison of recent parametric neuroreceptor mapping approaches based on measurements with the high affinity PET radioligands [11C]FLB 457 and [11C]WAY 100635 (2006) (55)
[11C]Vinpocetine: a prospective peripheral benzodiazepine receptor ligand for primate PET studies (2005) (53)
Metabolism of the PET ligand [11C]SCH 23390. Identification of two radiolabelled metabolites with HPLC (1994) (53)
Distribution of remoxipride to the human brain and central D2‐ dopamine receptor binding examined in vivo by PET (1990) (52)
In vitro and in vivo characterisation of nor-β-CIT: a potential radioligand for visualisation of the serotonin transporter in the brain (1997) (52)
QTc interval prolongation and antipsychotic drug treatments: focus on sertindole. (2005) (52)
Measurement of serotonin transporter binding with PET and [11C]MADAM: A test–retest reproducibility study (2006) (51)
Dopamine D1 receptor number — a sensitive PET marker for early brain degeneration in Huntington's disease (2005) (50)
Radioligands for the study of brain 5-HT(1A) receptors in vivo--development of some new analogues of way. (2000) (49)
NURR1 promoter polymorphisms: Parkinson's disease, schizophrenia, and personality traits (2003) (49)
Maps of receptor binding parameters in the human brain — a kinetic analysis of PET measurements (2004) (49)
Dopamine D2 receptor density in the limbic striatum is related to implicit but not explicit movement sequence learning (2010) (49)
Association between striatal and extrastriatal dopamine D2-receptor binding and social desirability (2010) (49)
Central D1- and D2-receptor occupancy during antipsychotic drug treatment (1990) (48)
Pindolol binding to 5-HT1A receptors in the human brain confirmed with positron emission tomography (1999) (48)
PET measurement of serotonin transporter occupancy: a comparison of escitalopram and citalopram. (2007) (48)
Brain imaging of schizophrenia—the dopamine hypothesis (1997) (47)
Carbon-11 labelling of eticlopride in two different positions--a selective high-affinity ligand for the study of dopamine D-2 receptors using PET. (1990) (47)
High 5-HT2 receptor occupancy in clozapine treated patients demonstrated by PET (2005) (47)
Diurnal and seasonal variation of the brain serotonin system in healthy male subjects (2015) (47)
In vivo evidence of a functional association between immune cells in blood and brain in healthy human subjects (2016) (47)
Low striatal and extra-striatal D2 receptor occupancy during treatment with the atypical antipsychotic sertindole (2002) (46)
A comparison of recent parametric neuroreceptor mapping approaches based on measurements with the high affinity PET radioligands [11C]FLB 457 and [11C]WAY 100635 (2006) (46)
Effects of age, BMI and sex on the glial cell marker TSPO — a multicentre [11C]PBR28 HRRT PET study (2019) (46)
Positron emission tomographic analysis of dose-dependent MDL 100,907 binding to 5-hydroxytryptamine-2A receptors in the human brain. (1998) (45)
Drug distribution in man: a positron emission tomography study after oral administration of the labelled neuroprotective drug vinpocetine (2002) (44)
PET imaging of [11C]PBR28 in Parkinson’s disease patients does not indicate increased binding to TSPO despite reduced dopamine transporter binding (2018) (44)
The PET radioligand [carbonyl-(11)C]desmethyl-WAY-100635 binds to 5-HT(1A) receptors and provides a higher radioactive signal than [carbonyl-(11)C]WAY-100635 in the human brain. (2002) (44)
Occupancy of 5-HT1A receptors by clozapine in the primate brain: a PET study (2003) (43)
Selective D1- and D2-dopamine receptor blockade both induces akathisia in humans — a PET study with [11C]SCH 23390 and [11C]raclopride (2005) (43)
Pharmacokinetics and dosimetry of iodine-123 labelled PE2I in humans, a radioligand for dopamine transporter imaging (1998) (43)
CSF GABA is reduced in first-episode psychosis and associates to symptom severity (2017) (42)
Dopamine D1-receptor binding in the living human brain. (1986) (42)
A PET study on regional coexpression of 5-HT1A receptors and 5-HTT in the human brain (2007) (42)
Error Analysis for Quantification of [11C]FLB 457 Binding to Extrastriatal D2 Dopamine Receptors in the Human Brain (2001) (42)
[125I]β-CIT-FE and [125I]β-CIT-FP are superior to [125I]β-CIT for dopamine transporter visualization: Autoradiographic evaluation in the human brain (1997) (42)
Implications of brain imaging for the management of schizophrenia (1998) (42)
A PET study of D(1)-like dopamine receptor ligand binding during altered endogenous dopamine levels in the primate brain. (1999) (41)
Dopamine D2/3 receptor occupancy of apomorphine in the nonhuman primate brain—A comparative PET study with [11C]raclopride and [11C]MNPA (2009) (41)
Modeling of PET data in CNS drug discovery and development (2013) (41)
Serotonin transporter occupancy with TCAs and SSRIs: a PET study in patients with major depressive disorder (2012) (40)
Test-retest reliability of central [11C]raclopride binding at high D2 receptor occupancy. A PET study in haloperidol-treated patients (1996) (40)
Modulation of striatal dopamine D1 binding by cognitive processing (2009) (39)
A Comparison of Gray Matter Density in Restless Legs Syndrome Patients and Matched Controls Using Voxel‐Based Morphometry (2010) (39)
Use of PET and the radioligand [carbonyl-(11)C]WAY-100635 in psychotropic drug development. (2000) (38)
Quantification of serotonin transporter availability with [11C]MADAM — A comparison between the ECAT HRRT and HR systems (2010) (38)
[11C]NNC 687 and [11C]NNC 756, dopamine D-1 receptor ligands. Preparation, autoradiography and PET investigation in monkey. (1993) (37)
Synthesis of carbon-11 labelled SCH 39166, a new selective dopamine D-1 receptor ligand, and preliminary PET investigations. (1991) (37)
Applications of a computerized adjustable brain atlas in positron emission tomography. (1986) (37)
Effects of age, BMI and sex on the glial cell marker TSPO - a multicentre [11C]PBR28 HRRT PET study (2019) (37)
Confirmation of Fenfluramine Effect on 5-HT1B Receptor Binding of [11C]AZ10419369 using an Equilibrium Approach (2012) (35)
Quantification of serotonin transporter availability with [11C]MADAM — A comparison between the ECAT HRRT and HR systems (2010) (35)
Dopamine D1 receptor availability is related to social behavior: A positron emission tomography study (2014) (35)
Large Variation in Brain Exposure of Reference CNS Drugs: a PET Study in Nonhuman Primates (2015) (34)
Clozapine binds preferentially to cortical D1-like dopamine receptors in the primate brain: a PET study (2006) (34)
PET analysis of the 5-HT2A receptor inverse agonist ACP-103 in human brain. (2008) (34)
Assessment of simplified ratio-based approaches for quantification of PET [11C]PBR28 data (2017) (34)
GABAA receptor availability is not altered in adults with autism spectrum disorder or in mouse models (2018) (34)
Non-equipotent doses partly explain differences among antipsychotics – implications of PET studies (2000) (33)
Muscle biopsy findings, conduction velocity and refractory period of single motor nerve fibres in schizophrenia. (1987) (33)
Brain Uptake and Plasma Metabolism of [11C]Vinpocetine: A Preliminary PET Study in a Cynomolgus Monkey (1999) (33)
Comparison of D2 dopamine receptor occupancy after oral administration of quetiapine fumarate immediate-release and extended-release formulations in healthy subjects (2011) (32)
[(11)C]PE2I: a highly selective radioligand for PET examination of the dopamine transporter in monkey and human brain. (2003) (32)
Mapping of Central D2Dopamine Receptors in Man Using [11C]Raclopride: PET with Anatomic Standardization Technique (1999) (31)
Pharmacokinetics and dopamine d2 and serotonin 5-ht2a receptor occupancy of paliperidone in healthy subjects: two open-label, single-dose studies (PAL-115) (2007) (31)
Quantitative PET analyses of regional [11C]PE2I binding to the dopamine transporter — Application to juvenile myoclonic epilepsy (2012) (31)
Radiosynthesis of the candidate β‐amyloid radioligand [11C]AZD2184: Positron emission tomography examination and metabolite analysis in cynomolgus monkeys (2010) (31)
PIII‐57 (2006) (31)
An open clinical and biochemical study of ritanserin in acute patients with schizophrenia (1994) (31)
Validity and reliability of extrastriatal [11C]raclopride binding quantification in the living human brain (2019) (30)
Positron emission tomographic evaluation of the putative dopamine-D3 receptor ligand, [ 11 C ]RGH-1756 in the monkey brain (2004) (30)
PET study of the M1-agonists [11C]xanomeline and [11C]butylthio-TZTP in monkey and man. (1996) (30)
Positron emission tomographic analysis of dose-dependent NAD-299 binding to 5-hydroxytryptamine-1A receptors in the human brain (2003) (30)
A PET study in healthy subjects of brain exposure of 11C-labelled osimertinib – A drug intended for treatment of brain metastases in non-small cell lung cancer (2020) (30)
Preparation of [76Br]FLB 457 and [76Br]FLB 463 for examination of striatal and extrastriatal dopamine D-2 receptors with PET. (1996) (29)
Test–retest reliability of [11C]AZ10419369 binding to 5-HT1B receptors in human brain (2014) (28)
Brain Age Prediction Reveals Aberrant Brain White Matter in Schizophrenia and Bipolar Disorder: A Multisample Diffusion Tensor Imaging Study. (2020) (28)
Norepinephrine transporter occupancy in the human brain after oral administration of quetiapine XR. (2013) (28)
Decreased thalamic D 2 / D 3 receptor binding in drug-naive patients with schizophrenia : a PET study with [ 11 C ] FLB 457 (2003) (28)
Development of a PET radioligand for the central 5-HT1B receptor: radiosynthesis and characterization in cynomolgus monkeys of eight radiolabeled compounds. (2011) (28)
Quantitative Analysis of 18F-(E)-N-(3-Iodoprop-2-Enyl)-2β-Carbofluoroethoxy-3β-(4′-Methyl-Phenyl) Nortropane Binding to the Dopamine Transporter in Parkinson Disease (2015) (28)
Dose-dependent binding of AZD3783 to brain 5-HT1B receptors in non-human primates and human subjects: a positron emission tomography study with [11C]AZ10419369 (2011) (28)
The International Journal of Neuropsychopharmacology. (1998) (27)
Effect of clozapine and risperidone on 5-HT2 and D2-dopamine receptor binding in the post-mortem human brain. An autoradiographic study (1995) (27)
Search for correlations between serotonin 5-HT1A receptor expression and cognitive functions—a strategy in translational psychopharmacology (2006) (27)
Radiosynthesis and autoradiographic evaluation of [11C]NAD-299, a radioligand for visualization of the 5-HT1A receptor. (1999) (27)
Extrastriatal dopamine D2 receptor binding in Huntington's disease (2011) (27)
[11C]Ro 15-4513, a ligand for visualization of benzodiazepine receptor binding (1992) (27)
Evaluation of Two Automated Methods for PET Region of Interest Analysis (2014) (26)
Quantification of Blood Flow-Dependent Component in Estimates of Beta-Amyloid Load Obtained Using Quasi-Steady-State Standardized Uptake Value Ratio (2015) (26)
Improved mapping and quantification of serotonin transporter availability in the human brainstem with the HRRT (2012) (26)
Quantitative analysis of 18F-FE-PE2I binding to the dopamine transporter in Parkinson’s disease (2015) (26)
New halogenated [11C]WAY analogues, [11C]6FPWAY and [11C]6BPWAY--radiosynthesis and assessment as radioligands for the study of brain 5-HT1A receptors in living monkey. (2001) (26)
PET examination of central D2 dopamine receptor occupancy in relation to extrapyramidal syndromes in patients being treated with neuroleptic drugs. (1993) (26)
Positron emission tomography imaging of 5-hydroxytryptamine1B receptors in Parkinson's disease (2014) (25)
Identification of positron emission tomography (PET) tracer candidates by prediction of the target-bound fraction in the brain (2014) (25)
Relationship of dopamine D1 receptor binding in striatal and extrastriatal regions to cognitive functioning in healthy humans (2011) (25)
PET imaging of neuroreceptors in schizophrenia (1995) (25)
Arterial Input Function Derived from Pairwise Correlations Between PET-image Voxels (2013) (25)
D2 occupancy, extrapyramidal side effects and antipsychotic drug treatment: a pilot study with sertindole in healthy subjects (1997) (25)
PET-Determination of Robalzotan (NAD-299) Induced 5-HT1A Receptor Occupancy in the Monkey Brain (2000) (25)
Fenfluramine Reduces [11C]Cimbi-36 Binding to the 5-HT2A Receptor in the Nonhuman Primate Brain (2017) (25)
SERT and NET occupancy by venlafaxine and milnacipran in nonhuman primates: a PET study (2013) (24)
Ligand metabolites in plasma during PET‐studies with the 11C‐labelled dopamine antagonists, raclopride, SCH 23390 and N‐methylspiroperidol (1992) (24)
Lipophilic metabolite of [123I]β‐CIT in human plasma may obstruct quantitation of the dopamine transporter (1995) (24)
Characterization of C‐11 or I‐123 Labelled β‐CIT‐FP and β‐CIT‐FE Metabolism Measured in Monkey and Human Plasma. Identification of Two Labelled Metabolites with HPLC (1996) (24)
Characterization of bromine-76-labelled 5-bromo-6-nitroquipazine for PET studies of the serotonin transporter. (1999) (24)
PET examination of three potent cocaine derivatives as specific radioligands for the serotonin transporter. (1999) (24)
Effects of amphetamine on the human brain opioid system – a positron emission tomography study (2012) (24)
Dopamine receptors in schizophrenia (1996) (24)
Test-retest reproducibility of dopamine D2/3 receptor binding in human brain measured by PET with [11C]MNPA and [11C]raclopride (2013) (23)
GABAA receptor occupancy by subtype selective GABAAα2,3 modulators: PET studies in humans (2016) (23)
Central 5-HT2A and D2 dopamine receptor occupancy after sublingual administration of ORG 5222 in healthy men (1997) (23)
Brain Dopaminergic Systems: Imaging with Positron Tomography (2012) (23)
Carbon-11 epidepride: a suitable radioligand for PET investigation of striatal and extrastriatal dopamine D2 receptors. (1999) (22)
Test-retest reliability and convergent validity of (R)-[11C]PK11195 outcome measures without arterial input function (2018) (22)
Carbon-11 pb-12: an attempt to visualize the dopamine d(4) receptor in the primate brain with positron emission tomography. (2000) (22)
D1-Dopamine Receptor Availability in First-Episode Neuroleptic Naive Psychosis Patients (2019) (22)
A PET study of [11C]β-CIT-FE binding to the dopamine transporter in the monkey and human brain (2000) (22)
Two NOTCH4 polymorphisms and their relation to schizophrenia susceptibility and different personality traits (2003) (22)
Development of rapid multistep carbon-11 radiosynthesis of the myeloperoxidase inhibitor AZD3241 to assess brain exposure by PET microdosing. (2015) (22)
Brain neuroreceptor density and personality traits: towards dimensional biomarkers for psychiatric disorders (2018) (22)
Age-related loss of olfactory sensitivity: Association to dopamine transporter binding in putamen (2009) (22)
Selective synthesis of racemic 1-11C-labelled norepinephrine, octopamine, norphenylephrine and phenylethanolamine using [11C]nitromethane. (1994) (21)
18F-MCL-524, an 18F-Labeled Dopamine D2 and D3 Receptor Agonist Sensitive to Dopamine: A Preliminary PET Study (2014) (21)
Quantitative PET Analysis of the Dopamine D2 Receptor Agonist Radioligand 11C-(R)-2-CH3O-N-n-Propylnorapomorphine in the Human Brain (2009) (21)
Reliability of volumetric and surface-based normalisation and smoothing techniques for PET analysis of the cortex: A test-retest analysis using [11C]SCH-23390 (2017) (21)
Utilization of radioligands in schizophrenia research. (1995) (21)
Palladium mediated ¹¹C-cyanation and characterization in the non-human primate brain of the novel mGluR5 radioligand [¹¹C]AZD9272. (2013) (20)
The genetic architecture of human brainstem structures and their involvement in common brain disorders (2019) (20)
PET examination of [(11)C]5-methyl-6-nitroquipazine, a radioligand for visualization of the serotonin transporter. (2002) (20)
Low background and high contrast PET imaging of amyloid-β with [11C]AZD2995 and [11C]AZD2184 in Alzheimer’s disease patients (2013) (20)
PET Studies on Brain Energy Metabolism and Dopamine Receptors in Schizophrenic Patients and Monkeys (1985) (20)
The new selective D2-dopamine receptor antagonist raclopride--pharmacokinetics, safety and tolerability in healthy males. (1989) (20)
Quantitative Analysis of Amyloid Deposition in Alzheimer Disease Using PET and the Radiotracer 11C-AZD2184 (2014) (20)
Brain exposure of the ATM inhibitor AZD1390 in humans - a positron emission tomography (PET) study. (2020) (20)
D(2)- and 5-HT(2) receptor occupancy in high-dose neuroleptic-treated patients. (1998) (20)
Radioiodinated SB 207710 as a radioligand in vivo: imaging of brain 5-HT4 receptors with SPET (2003) (20)
5‐HT1B receptor imaging and cognition: A positron emission tomography study in control subjects and parkinson's disease patients (2015) (20)
The pyridinyl-6 position of WAY-100635 as a site for radiofluorination--effect on 5-HT1A receptor radioligand behavior in vivo. (2004) (19)
Transcription factor AP-2β genotype, striatal dopamine D2 receptor density and cerebrospinal fluid monoamine metabolite concentrations in humans (2004) (19)
Atomoxetine occupies the norepinephrine transporter in a dose-dependent fashion: A PET study in nonhuman primate brain using ( S , S )-[18F]FMeNER-D2 (2006) (19)
Optimal Acquisition Time Window and Simplified Quantification of Dopamine Transporter Availability Using 18F-FE-PE2I in Healthy Controls and Parkinson Disease Patients (2016) (19)
PET studies of D2‐receptor binding in striatal and extrastriatal brain regions: Biochemical support in vivo for separate dopaminergic systems in humans (2010) (19)
11C-carbonylation reactions using gas–liquid segmented microfluidics (2015) (19)
Different brain radioactivity curves in a PET study with [11C]beta-CIT labelled in two different positions. (1999) (19)
PET STUDIES OF DOPAMINE RECEPTORS IN RELATION TO ANTIPSYCHOTIC DRUG TREATMENT (1992) (19)
N-oxide analogs of WAY-100635: new high affinity 5-HT(1A) receptor antagonists. (2005) (18)
Low serotonin1B receptor binding potential in the anterior cingulate cortex in drug-free patients with recurrent major depressive disorder (2016) (18)
Support for limited brain availability of tyrosine in patients with schizophrenia. (2005) (18)
Oral administration of NNC 756 — a placebo controlled PET study of D1-dopamine receptor occupancy and pharmacodynamics in man (1995) (18)
Amphetamine Decreases α2C-Adrenoceptor Binding of [11C]ORM-13070: A PET Study in the Primate Brain (2015) (18)
Synthesis of 11C-labelled (R)-OHDMI and CFMME and their evaluation as candidate radioligands for imaging central norepinephrine transporters with PET. (2007) (18)
Serotonin transporter availability in adults with autism—a positron emission tomography study (2020) (18)
A cross-validation study on the relationship between central D2 receptor occupancy and serum perphenazine concentration (2004) (17)
Synthesis and Positron Emission Tomography Evaluation of Three Norepinephrine Transporter Radioligands: [C-11]Desipramine, [C-11]Talopram and [C-11]Talsupram (2005) (17)
The MINDVIEW project: First results (2018) (17)
NET occupancy by clomipramine and its active metabolite, desmethylclomipramine, in non-human primates in vivo (2011) (17)
Lack of effect of reserpine-induced dopamine depletion on the binding of the dopamine-D3 selective radioligand, [11C]RGH-1756 (2005) (17)
Positron Emission Tomography in Schizophrenia (1990) (16)
Central D2 receptor occupancy and effects of zuclopenthlxol acetate in humans (1995) (16)
Neurotransmitter receptor imaging in Alzheimer's disease. (1987) (16)
Synthesis of ([(11)C]carbonyl)raclopride and a comparison with ([(11)C]methyl)raclopride in a monkey PET study. (2015) (16)
Disease activity in rheumatoid arthritis is inversely related to cerebral TSPO binding assessed by [11C]PBR28 positron emission tomography (2019) (16)
The development of a GPR44 targeting radioligand [11C]AZ12204657 for in vivo assessment of beta cell mass (2018) (16)
Distinct regional age effects on [11C]AZ10419369 binding to 5-HT1B receptors in the human brain (2014) (16)
New alpha(1)-adrenoceptor antagonists derived from the antipsychotic sertindole - carbon-11 labelling and pet examination of brain uptake in the cynomolgus monkey. (2004) (15)
Positron Emission Tomography Studies on Dopamine Receptors in Schizophrenia (1995) (15)
Distinct binding of amyloid imaging ligands to unique amyloid‐β deposited in the presubiculum of Alzheimer's disease (2015) (15)
Synthesis and PET evaluation of (R)‐[S‐methyl‐11C]thionisoxetine, a candidate radioligand for imaging brain norepinephrine transporters (2006) (15)
Effect of risperidone on high-affinity state of dopamine D2 receptors: a PET study with agonist ligand [11C](R)-2-CH3O-N-n-propylnorapomorphine. (2011) (15)
Cerebral uptake of [ethyl-11C]vinpocetine and 1-[11C]ethanol in cynomolgous monkeys: a comparative preclinical PET study. (2002) (15)
Positron emission tomography--examination of chemical transmission in the living human brain. Development of radioligands. (1992) (15)
Syntheses of [123I]-, [125I]- and unlabelled (S)-3-iodo-5,6-dimethoxy-N-[(1-ethyl-2-pyrrolidinyl)methyl]salicylamide (NCQ 298), selective ligands for the study of dopamine D-2 receptors. (1990) (15)
[18F] beta-CIT-FP is superior to [11C] beta-CIT-FP for quantitation of the dopamine transporter. (1997) (15)
11C-SCH 39166, a selective ligand for visualization of dopamine-D1 receptor binding in the monkey brain using PET (2005) (15)
Recent developments in PET scan imaging of neuroreceptors in schizophrenia. (1995) (15)
Age-related diurnal effect on D2 receptor binding: a preliminary PET study. (2008) (15)
P.1.e.019 PET-measured occupancy of the norepinephrene transporter by extended release quetiapine fumarate (quetiapine XR) in brains of healthy subjects (2008) (14)
Remoxipride — a new potential antipsychotic drug (1988) (14)
PET scanning--a new tool in clinical psychopharmacology. (1988) (14)
Increased number of monocytes and plasma levels of MCP‐1 and YKL‐40 in first‐episode psychosis (2018) (14)
Preparation and preliminary positron emission tomography studies of 11C-Ro 15-1788, a selective benzodiazepine receptor antagonist. (1984) (14)
Serotonin concentration enhancers at clinically relevant doses reduce [11C]AZ10419369 binding to the 5-HT1B receptors in the nonhuman primate brain (2018) (13)
Z-IQNP: a potential radioligand for SPECT imaging of muscarinic acetylcholine receptors in Alzheimer’s disease (2000) (13)
Occupancy of the central benzodiazepine receptors during benzodiazepine treatment determined by PET (1991) (13)
Radiolabeling of the cannabinoid receptor agonist AZD1940 with carbon-11 and PET microdosing in non-human primate. (2013) (13)
Iodine-123 labelled Z-(R,R)-IQNP: a potential radioligand for visualization of M1 and M2 muscarinic acetylcholine receptors in Alzheimer’s disease (1999) (13)
Pharmacokinetics of Raclopride Formulations (1992) (13)
[11C]metaraminol, a false neurotransmitter: preparation, metabolite studies and positron emission tomography examination in monkey. (1996) (13)
Evaluation of SCH 39166 as PET ligand for central D1 dopamine receptor binding and occupancy in man (1995) (13)
[11C]beta-CIT-FE, a radioligand for quantitation of the dopamine transporter in the living brain using positron emission tomography. (1996) (13)
Preparation of [1-11C]dopamine, [1-11C]p-tyramine and [1-11C]m-tyramine. Autoradiography and PET examination of [1-11C]dopamine in primates. (1993) (12)
11C- and 76Br-labelled NNC 22-0010, selective dopamine D1 receptor radioligands for PET. (1996) (12)
Quantitative analysis of ( 11 C)AZ10419369 binding to 5-HT 1B receptors in human brain (2011) (12)
Development of 123I-labelled NNC 13-8241 as a radioligand for SPECT visualization of benzodiazepine receptor binding. (1996) (12)
Contribution of non-genetic factors to dopamine and serotonin receptor availability in the adult human brain (2016) (12)
Central Benzodiazepine Receptor Binding Studied with 11-C Labelled Ro 15-1788 and Positron Emission Tomography (1986) (12)
SPET imaging of central muscarinic acetylcholine receptors with iodine-123 labelled E-IQNP and Z-IQNP (2001) (12)
Glia Imaging Differentiates Multiple System Atrophy from Parkinson's Disease: A Positron Emission Tomography Study with [11C]PBR28 and Machine Learning Analysis (2021) (12)
Investigation of the Metabolites of (S,S)-[11C]MeNER in Humans, Monkeys and Rats (2008) (12)
A PET study with [11C]AZ10419369 to determine brain 5-HT1B receptor occupancy of zolmitriptan in healthy male volunteers (2013) (12)
The metabotropic glutamate receptor 5 radioligand [11C]AZD9272 identifies unique binding sites in primate brain (2018) (11)
Guidelines for biological Treatment of Schizophrenia, : Part 1: Acute Treatment of Schizophrenia and Part 2: Long-term Treatment of Schizophrenia (2005) (11)
505 D1-Dopamine receptors in schizophrenia examined by pet (1997) (11)
Bromine-76 and carbon-11 labelled NNC 13-8199, metabolically stable benzodiazepine receptor agonists as radioligands for positron emission tomography (PET) (1997) (11)
The dopamine D1 receptor agonist (S)‐[11C]N‐methyl‐NNC 01‐0259 is not sensitive to changes in dopamine concentration—a positron emission tomography examination in the monkey brain (2013) (11)
ドーパミンD‐2受容体の研究のための選択的リガンドである,(S)‐3‐ヨウ化‐5,6‐ジメトキシ‐N‐[(1‐エチル‐2‐ピロリジニル)メチル]サリチルアミド(NCQ298)と,その〔123I〕,〔125I〕ラベル化物の合成 (1990) (10)
The relevance of serotonergic mechanisms in the treatment of schizophrenia has not been confirmed (1997) (10)
A PET study comparing receptor occupancy by five selective cannabinoid 1 receptor antagonists in non-human primates (2016) (10)
Radiochemical labelling of the dopamine D3 receptor ligand RGH‐1756 (2000) (10)
Short communication Post-mortem human brain autoradiography of the norepinephrine transporter using (S,S)-( 18 F)FMeNER-D 2 (2005) (10)
Differential Effect of APOE Alleles on Brain Glucose Metabolism in Targeted Replacement Mice: An [18F]FDG-μPET Study (2017) (10)
P.1.c.022 PET-measured D2, 5-HT2, and norepinephrine transporter (NET) occupancy by quetiapine and N-desalkyl-quetiapine in non-human primates (2007) (10)
Synthesis of [ethyl‐18F]fluororaclopride for the in vivo study of dopamine D2 receptors using PET (1989) (10)
Synthesis, Radiolabeling, and In Vivo Pharmacokinetic Evaluation of the Amyloid Beta Radioligand [11C]AZD4694 in Nonhuman Primates (2014) (10)
Pulmonary PET imaging confirms preferential lung target occupancy of an inhaled bronchodilator (2019) (10)
PET-determination of benzodiazepine receptor binding in studies on alcoholism. (1994) (10)
Stereoselective binding of 11C‐labelled piquindone (Ro 22–1319) to dopamine‐D2 receptors in the living human brain (1987) (10)
[125I] beta-CIT-FE and [125I] beta-CIT-FP are superior to [125I] beta-CIT for dopamine transporter visualization: autoradiographic evaluation in the human brain. (1997) (9)
Xanomeline, A Specific M1 Agonist: Early Clinical Studies (1994) (9)
PET-examination and metabolite evaluation in monkey of [(11)C]NAD-299, a radioligand for visualisation of the 5-HT(1A) receptor. (2002) (9)
[11C]SCH23390 binding to the D1-dopamine receptor in the human brain—a comparison of manual and automated methods for image analysis (2018) (9)
Imaging of dopamine receptors using PET and SPECT (1992) (9)
The pro-psychotic metabotropic glutamate receptor compounds fenobam and AZD9272 share binding sites with monoamine oxidase-B inhibitors in humans (2020) (9)
Radiosynthesis and evaluation of new α1-adrenoceptor antagonists as PET radioligands for brain imaging. (2013) (9)
Serotonin transporter occupancy by escitalopram and citalopram in the non-human primate brain: a [11C]MADAM PET study (2015) (9)
Mesial temporal lobe epilepsy is associated with limbic reductions in serotonin 5HT1A receptor binding (2001) (9)
Synthesis of 2β‐carbomethoxy‐3β‐(4‐[76Br]bromophenyl)tropane ([76Br]β‐CBT), a pet tracer for in vivo imaging of the dopamine uptake sites (1995) (9)
Kinfitr – an open source tool for reproducible PET modelling: validation and evaluation of test-retest reliability (2020) (8)
Discovery and Preclinical Validation of [(11)C]AZ13153556, a Novel Probe for the Histamine Type 3 Receptor. (2016) (8)
High-resolution PET imaging reveals subtle impairment of the serotonin transporter in an early non-depressed Parkinson’s disease cohort (2020) (8)
Effects of cocaine on [11C]norepinephrine and [11C]β-CIT uptake in the primate peripheral organs measured by PET (1996) (8)
[11C]cyclopropyl-FLB 457: a PET radioligand for low densities of dopamine D2 receptors. (2008) (8)
Characterization of [11C]Lu AE92686 as a PET radioligand for phosphodiesterase 10A in the nonhuman primate brain (2016) (8)
Mapping the distribution of serotonin transporter in the human brainstem with high-resolution PET: Validation using postmortem autoradiography data (2016) (8)
Development of radioligands for the dopamine transporter (1996) (8)
Brain Dopamine Receptors in Schizophrenia: PET Problems-Reply (1988) (8)
Initial human studies with single-photon emission tomography using iodine-123 labelled 3-(5-cyclopropyl-1,2,4-oxadiazo-3-yl)-7-iodo-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]-benzodiazepine (NNC 13-8241) (1996) (8)
The metabolite pattern of [123I]β-CIT determined with a gradient HPLC method (1995) (8)
Abstract CT013: Osimertinib displays high brain exposure in healthy subjects with intact blood-brain barrier: a microdose positron emission tomography (PET) study with11C-labelled osimertinib (2018) (8)
Clinical melperone treatment blocks D2‐dopamine receptors in the human brain as determined by PET (1989) (8)
Low convergent validity of [11C]raclopride binding in extrastriatal brain regions: A PET study of within-subject correlations with [11C]FLB 457 (2020) (8)
[11C]AZ10419096 - a full antagonist PET radioligand for imaging brain 5-HT1B receptors. (2017) (8)
Joint explorative analysis of neuroreceptor subsystems in the human brain: application to receptor–transporter correlation using PET data (2004) (7)
Half-life of receptor occupancy--a meaningless concept. (2005) (7)
Autoradiographic evaluation of [11C]vinpocetine binding in the human postmortem brain. (2002) (7)
Quantitative determination of D2 dopamine receptor characteristics in healthy human subjects and psychiatric patients. (1987) (7)
Fluorine-18-labelled NCQ 115, a selective dopamine D-2 receptor ligand. Preparation and positron emission tomography. (1994) (7)
Two C-Methyl Derivatives of [11C]WAY-100635 – Effects of an Amido α-Methyl Group on Metabolism and Brain 5-HT1A Receptor Radioligand Behavior in Monkey* (2005) (7)
Cerebrospinal fluid levels of sphingolipids associate with disease severity in first episode psychosis patients (2018) (7)
Effect of clinically relevant doses of vortioxetine and citalopram on serotonergic PET markers in the nonhuman primate brain (2019) (7)
Short Communication Fenfluramine-Induced Serotonin Release Decreases ( 11 C)AZ10419369 Binding to 5-HT 1B -Receptors in the Primate Brain (2010) (7)
Recent advances in psychiatric brain imaging. (1990) (7)
STUDIES OF SCHIZOPHRENIA WITH POSITRON CT (1984) (7)
Is dopamine D1 receptor availability related to social behavior? A positron emission tomography replication study (2017) (7)
[11C]NNC 22-0215, a metabolically stable dopamine D1 radioligand for PET. (1998) (6)
PET for drug development. (2004) (6)
Use of graphical techniques for error evaluation (1987) (6)
Effects of sevoflurane anaesthesia on radioligand binding to monoamine oxidase-B in vivo (2020) (6)
Thalamic dopamine D2-receptor availability in schizophrenia: a study on antipsychotic-naive patients with first-episode psychosis and a meta-analysis (2021) (6)
Influence of rate of administration of raclopride on akathisia and prolactin response (1994) (6)
Publisher Correction: Common brain disorders are associated with heritable patterns of apparent aging of the brain (2019) (6)
Positron emission tomography shows high specific uptake of racemic carbon-11 labelled norepinephrine in the primate heart (1994) (6)
P76.72 A PET and MRI Study Exploring Osimertinib Brain Exposure and Efficacy in EGFRm NSCLC CNS Metastases (2021) (6)
Evaluation and metabolite studies of 125I- and 123I-labelled E-(R,R)-IQNP: potential radioligands for visualization of M1 muscarinic acetylcholine receptors in brain. (1998) (5)
Synthesis of nor-β-CIT, β-CIT and trimethylstannyl-β-CT (1995) (5)
Dopamine D2/D3 receptor occupancy of apomorphine evaluated with the agonist radioligand [11C]MNPA and the antagonist radioligand [11C]Raclopride. A PET evaluation in the non-human primate brain (2006) (5)
NCQ 298, a new selective iodinated salicylamide ligand for the labelling of dopamine D2 receptors (2005) (5)
β-Amyloid binding in elderly subjects with declining or stable episodic memory function measured with PET and [11C]AZD2184 (2015) (5)
[11C]raclopride positron emission tomography study of dopamine‐D2/3 receptor binding in patients with severe major depressive episodes before and after electroconvulsive therapy and compared to control subjects (2020) (5)
Toxicity, mutagenicity, and behavioral effects of beta-CIT, a ligand for dopamine transporter exploration by SPECT. (1998) (5)
Autoradiographic comparison of [125I]epidepride and [125I]NCQ 298 binding to human brain extrastriated dopamine receptors. (1997) (5)
Quantification and reliability of [11C]VC - 002 binding to muscarinic acetylcholine receptors in the human lung — a test-retest PET study in control subjects (2020) (5)
PET analysis of alcohol interaction with the brain disposition of [11C]flumazenil (2005) (5)
Kinfitr — an open-source tool for reproducible PET modelling: validation and evaluation of test-retest reliability (2020) (5)
AZD4694: Fluorinated Positron Emission Tomography (PET) radioligand for detection of β-amyloid deposits (2009) (5)
Potential Effect of Prolonged Sevoflurane Anesthesia on the Kinetics of [11C]Raclopride in Non-human Primates (2017) (4)
Dopamine Receptor Occupancy and Plasma Haloperidol Levels-Reply (1989) (4)
Dose-dependent binding of AZD3783 to brain 5-HT 1B receptors in non-human primates and human subjects: a positron emission tomography study (2011) (4)
Dr. Talvik and Colleagues Reply (2002) (4)
[Cerebral uptake and regional distribution of [11C]-vinpocetin after intravenous administration to healthy men: a PET study]. (2002) (4)
Reply to: New Meta- and Mega-analyses of Magnetic Resonance Imaging Findings in Schizophrenia: Do They Really Increase Our Knowledge About the Nature of the Disease Process? (2019) (4)
PET in Neuropsychiatric Drug Development (1995) (4)
Drug interaction studies with remoxipride (1990) (4)
Integrated Strategy for Use of Positron Emission Tomography in Nonhuman Primates to Confirm Multitarget Occupancy of Novel Psychotropic Drugs: An Example with AZD3676 (2016) (4)
The potential of positron-emission tomography for pharmacokinetic and pharmacodynamic studies of neuroleptics. (1989) (4)
PET-Determination of Central D1- and D2-Dopamine Receptor Occupancy in Neuroleptic Treated Schizophrenics (1987) (4)
Scatchard Analysis of the D2 Receptor Agonist [C-11]MNPA in the Monkey Brain Using PET (2005) (3)
PET evaluation of the partial dopamine D1 receptor agonist radioligands R- and S-[11C]N-Methyl-NNC 01-0259 (2006) (3)
Synthesis of nor-beta-CIT, beta-CIT and trimethylstannyl-beta-CT. (1995) (3)
COMT inhibition prevents the formation of lipophilic radiometabolites of catechols, — An example with (S)-[11C]N-methyl-NNC 01-0259 (2008) (3)
Interaction study between remoxipride and biperiden (2005) (3)
Potential for imaging the high-affinity state of the 5-HT1B receptor: a comparison of three PET radioligands with differing intrinsic activity (2019) (3)
Positron emission tomography studies on dopamine receptors in Schizophrenia. Discussion (1995) (3)
Preparation of a potential positron emission tomographic radioligand for the dopamine transporter (1994) (3)
RESEARCH ARTICLE Investigation of the Metabolites of (S,S)-( 11 C) MeNER in Humans, Monkeys and Rats (2009) (3)
New radioligands for pet-examination of central muscarinic receptors (1994) (3)
TSPO binding may also represent ‘resting’ microglia (2015) (3)
A PET study of [ 11 C ] β-CIT-FE binding to the dopamine transporter in the monkey and human brain (2000) (2)
S.26.03 A PET-study of extrastriatal D2-dopamine receptors (1997) (2)
Synthesis and Autoradiography of Novel F-18 Labeled Reversible Radioligands for Detection of Monoamine Oxidase B (2020) (2)
Dopamine D2/3 receptor occupancy of apomorphine in the non-human primate brain does not support the existence of two affinity states in vivo (2008) (2)
[11C]AZ10419369: A selective 5-HT1B receptor radioligand suitable for positron emission tomography (PET); Characterization in cynomolgus monkey brain (2008) (2)
[Cerebral uptake and metabolism of (11C) Vinpocetine in monkeys: PET studies]. (1999) (2)
Advancement in PET quantification using 3D-OP-OSEM PSF reconstruction with the HRRT (2008) (2)
Amphetamine decreases binding of the novel alpha2C-adrenoreceptor radioligand [11C]ORM-13070 in monkey brain (2010) (2)
Quantitative analyses of [11C]AZ10419369 binding to 5-HT1B receptors in the human brain (2008) (2)
In response to the letter “[11C]raclopride and extrastriatal binding to D2/3 receptors” (2019) (2)
Synthesis, Biodistribution, and Radiation Dosimetry of a Novel mGluR5 Radioligand: 18F-AZD9272 (2020) (2)
Decreased D1-dopamine receptor binding in drug naive schizophrenic patients examined by pet (1995) (2)
Radioactive metabolites of the 5-HT1A receptor pet radioligand, [carbonyl-11C]way-100635, measured in human plasma samples (2001) (2)
Test-retest variability of [C-11]raclopride in rat using PET/MRI (2012) (2)
Confirmation of fenfluramine effect on 5-HT1B binding of [11C]AZ10419369 using an equilibrium approach (2010) (2)
Serotonin 5-HT1A receptor binding and self-transcendence in healthy control subjects - a replication study using Bayesian hypothesis testing (2017) (2)
LIGAND SELECTION FOR PET STUDIES OF D1 DOPAMINE RECEPTORS. RELATIONSHIP BETWEEN DISTRIBUTION OF BINDING SITES AND mRNA FOR DAARPP32 IN THE HUMAN BRAIN (1992) (2)
Positron Emission Tomography (PET) Studies with Ligands for Cholinergic Receptors in the Human Brain (1995) (2)
Dopamine and Serotonin Receptor Occupancy in Patients Treated with Antipsychotics (1996) (2)
Visualization of Neuroreceptor Functions in the Living Human Brain (1989) (2)
Clozapine and dopamine D2 blockade. Authors' reply (2002) (1)
D-Amphetamine decreases 5-HT1B receptor binding of [11C]AZ10419369 in the monkey brain (2011) (1)
[18F]Flumazenil for central benzodiazepine receptor imaging and its comparison with [11C] in human brain (2007) (1)
Long-time persistence of D2 dopamine receptor occupancy after discontinuation of haloperidol decanoate (1996) (1)
Comparisons of central benzodiazepine receptor mapping tracers [18F]Flumazenil and [11C]Flumazenil presentation (2006) (1)
Pharmacokinetic analysis of plasma curves obtained after i.v. injection of the PET radioligand [11C] raclopride provides a likely explanation for rapid radioligand metabolism (2012) (1)
Quantification and wavelet-aided parametric imaging of cerebral amyloid using the HRRT PET-system and [18F]AZD4694 (2010) (1)
Serotonin 5-HT1A receptor binding and self-transcendence in healthy control subjects—a replication study using Bayesian hypothesis testing (2018) (1)
An HPLC-method for determination of ligand metabolism during PET studies with [11C]metaraminol and [11C]norepinephrine. (1995) (1)
P-4-61 Autoradiographic comparison of D2- and D3-dopamine receptor localization in the post mortem human brain using [125I]epidepride and [3H]PD 128907 (1995) (1)
Effect of amphetamine on dopamine D2 receptor binding in the primate brain with the agonist ligand [11C]MNPA (2005) (1)
Radiosynthesis of [11C]MNPA from the precursor (R)-(−)-2-hydroxy-10,11-acetonide-NPA and a preliminary test–retest PET analysis in monkey brain (2008) (1)
AZD4694: Fluorinated Positron Emission Tomography (PET) radioligand for detection of β-amyloid deposits (2009) (1)
Dopamine and cognitive aging: A strong relationship (2007) (1)
[18F]6FPWAY — a prospective 5-HT1A receptor radioligand — radiolabeling and pet examination in monkey — comparison with [11C]6FPWAY (2001) (1)
[18F]MCL-524, an 18F-labeled dopamine D2/D3 receptors agonist radioligand with higher binding signal than [11C]MNPA (2012) (1)
A comparison of amphetamine induced changes in agonist and antagonist radioligand binding potential on the dopamine D2 receptor in primate brain (2005) (1)
D2- and 5-HT2 receptor occupancy in “mega-dose” treated schizophrenic patients (1996) (1)
No association between cortical dopamine D2 receptor availability and cognition in antipsychotic-naive first-episode psychosis (2021) (1)
Quantitative analysis of dopamine D2 receptor binding in human brain using PET with an agonist radioligand [11C]MNPA (2008) (1)
COMT inhibition is a method for avoidance of lipophilic radiometabolites of catechols, exemplified with (S)-[C-11]N-methyl-NNC 01-0259 (2007) (1)
PET determination of robalzotan occupancy of 5-HT1A receptors in the monkey brain (1998) (1)
PET Studies in the Early Clinical Development of a New Antipsychotic (1995) (1)
145. Translocator protein (TSPO) as a biomarker of microglia activation: PET imaging using [11C]PBR28 in Parkinson’s disease (2013) (1)
Synthesis of [11C]2β-carbomethoxy-3β-(3′-iodo-4′-methyl, -ethyl and isopropyl phenyl)nortropane as potential radiotracers for examination of the serotonin transporter with positron emission tomography (2000) (1)
P2.14-33 An Open-Label PET-MRI Study to Determine Brain Exposure of Osimertinib in Patients with EGFR Mutant NSCLC and CNS Metastases (2019) (1)
A novel principle of radiotracer administration in human brain mapping: pet studies on brain uptake and distribution of orally and intravenously administered [11C]vinpocetine (2001) (1)
PET studies of D1 and D2 dopamine receptors in drug naive schizophrenic patients (1991) (1)
Preparation and Examination of Labelled Stereoisomers in Vivo by Pet (1995) (1)
Synthesis of five benzamide analogs. Comparison with positron emission tomography. (1991) (1)
PET Examination of Central D2 dopamine and 5‐HT2 Receptor Occupancy by Risperidone (1992) (1)
Striatai and extrastriatal D2-dopamine receptor occupancy during haloperidol and ciozapine treatment (1998) (1)
Comparison of beta-amyloid imaging using congo red and thioflavin T derivatives (2012) (1)
PET AND AUTORADIOGRAPHY OF BENZODIAZEPINE RECEPTOR BINDING WITH RADIOLABELLED FLUMAZENIL AND RO 15‐4513. (1992) (1)
Synthesis and binding properties of [3H]NNC 12-0781, a new radioligand for the dopamine reuptake system. (1995) (1)
Current concepts in schizophrenia: international symposia report new standards for assessment and treatment. Part I: Pathophysiology research prompts assessment updates. (1995) (1)
GABAA receptor occupancy by subtype selective GABAAα2,3 modulators: PET studies in humans (2016) (1)
[Swedish research in frontline. Positron emission tomography shows the brain's receptor functions in psychiatric diseases]. (1984) (1)
Radiolabeling, preliminary biological evaluation and pet examination in monkey of 5‐methyl‐6‐nitroquipazine — a potential serotonin transporter radioligand (2001) (1)
Dopamine D1 receptor availability is not associated with delusional ideation measures of psychosis proneness (2018) (1)
Cognitive Performance in Drug-naÏve First Episode Schizophrenia (FES) Patients (2015) (1)
Neurokinin-3 Receptor Binding in Guinea Pig, Monkey, and Human Brain: In Vitro and in Vivo Imaging Using the Novel Radioligand, [18F]Lu AF10628 (2016) (1)
Attenuation correction in PET-transmission vs. contour finding in the study of [/sup 11/C]raclopride binding (1993) (1)
Low convergent validity of FLB 457 (2020) (0)
Glia Imaging Differentiates Multiple System Atrophy from Parkinson's Disease: A Pet Study Using [ 11C ] PBR28 and Machine Learning Enhanced Analysis (2021) (0)
Evaluation of Two Automated Methods for PET Region of Interest Analysis (2014) (0)
Dr. Nordström and Colleagues Reply (1996) (0)
Synthesis of 11C-labeled (S,S)-CFMME and (R)-OHDMI and their evaluation as candidate radioligands for imaging norepinephrine transporters with PET (2006) (0)
PET STUDIES OF ATYPICAL ANTIPSYCHOTICS (2000) (0)
Striatal dopamine D2 receptor availability as a predictor of subsequent alcohol use in social drinkers. (2023) (0)
Dopamine transporter binding in patients with juvenile myoclonic epilepsy using [11C]PE2I and PET (2010) (0)
IMAGING DRUG DELIVERY TO THE CNS USING TRANSLATIONAL POSITRON EMISSION TOMOGRAPHY STUDIES (2013) (0)
The novel mGluR5 radioligand [ 11 C]AZ11696415: Palladium mediated 11 C-cyanation and initial in vivo characterization in the cynomolgus monkey brain using positron emission tomography (PET) (2010) (0)
Visualizing the central 5-HT1B receptor with PET in rats (2012) (0)
Dopamine transporter binding using [11C]PE2I and PET corrected for tissue heterogeneity and partial volume effect (2007) (0)
The dopamine hypothesis of schizophrenia : The role of pet (2004) (0)
P.2.115 PET examinations or thalamic D2 receptors in schizophrenic patients (2003) (0)
Development of PET Radioligands for the Quantitation of Serotonin Receptors in the Human Brain (1998) (0)
S-52-1 Pet-studies on the dopamine system in vivo (1996) (0)
On the pathophysiology of schizophrenia (2003) (0)
A radiopharmaceutical agent useful in benzodiazine radioiodinated benzodiazepine derivatives and their use in the diagnosis (1996) (0)
S.03.02 PET studies on the dopamine system in vivo (1996) (0)
Distribution of Serotonin Receptor Subtypes in the Post-Mortem Human Brain (1998) (0)
Extra-striatal dopamine receptors studied with [125I]epideprideIn VITRO and [[11C]FLB 457in vivo (1995) (0)
GLUTAMATERGIC NEUROTRANSMISSION IN PSYCHIATRIC DISORDERS (2016) (0)
Synthesis of [(CO)-C-11]Raclopride and a Comparison with [(CH3)-C-11]Raclopride in a Monkey PET Study (2015) (0)
Evaluation of Errors Using Graphical Techniques (1987) (0)
P.1.06 Limbic dopamine D2-receptor binding and social desirability (2009) (0)
Positron emission tomography shows high specific uptake of racemic carbon-11 labelled norepinephrine in the primate heart (2004) (0)
Effect of amphetamine on dopamine D2 receptors binding in the primate brain with the new agonist ligand [C-11]MNPA (2004) (0)
Mapping the distribution of serotonin transporter in the human brainstem with high-resolution PET: A template-based analysis (2014) (0)
A Voxelwise Analysis of the Relationship between White Matter Integrity and Impulsivity in Men with Schizophrenia (2004) (0)
[ 18 F]AZD4694 — A new PET radioligand for sensitive detection of β-amyloid deposits (2010) (0)
PET and antipsychotic drugs — background (2002) (0)
Decreased 5‐HT1A binding in mild Alzheimer's disease—A positron emission tomography study (2022) (0)
A new quantitative approach to estimate binding parameters reducing the effect of radiometabolites using three steps of kinetic analysis (2013) (0)
Editorial Board (2009) (0)
PET SCANNING OF DOPAMINE RECEPTORS AND PSYCHOSIS (1992) (0)
P.3.24 Lower 5-HT1A receptor binding in patients with borderline personality disorder: a PET study using [11C]WAY100635 (2008) (0)
DOPAMINERECEPTORS ANDNEUROLOGICALSIDE EFFECTS (2010) (0)
P.1.e.021 In vivo assessment of changes in serotonin release in the non-human primate brain using PET and [11C]AZ10419369 (2010) (0)
PET examination of the monkey heart with high specific radioactivity [11C]norepinephrine and [11C]metaraminol. (1995) (0)
Changes in cortical D1 receptor binding associated with training-induced changes in working memory capacity. (2009) (0)
5-HT1B receptor imaging in Parkinson's disease with 11C-AZ10419369 and positron emission tomography (2012) (0)
PET in the Development of Dopamine D1 Antagonists as New Potential Antipsychotic Drugs (1995) (0)
PET imaging of brain neurotransmission (2002) (0)
The application of positron emission tomography in psychiatry (1988) (0)
No "ceiling effect" observed with the exogenous dopamine agonist apomorphine - A PET study with the dopamine D-2 receptor agonist radioligand [C-11]MNPA and antagonist radioligand [C-11]Raclopride (2006) (0)
Detailed mapping of dopamine D2 receptors in the human limbic system using FLB 457 binding analysis in wavelet space (2001) (0)
Synthesis and Preclinical Evaluation of [11C]AZ11895530 for PET Imaging of the Serotonin 1A Receptor. (2022) (0)
Image derived input function using a multivariate analysis method based on pair-wise correlation between PET-image voxels (2012) (0)
TOBACCO SMOKING IN PSYCHIATRIC PATIENTS-A HARMFUL SELF-MEDICATION WITH NICOTINE? (2014) (0)
Microdosing of radiolabeled CNS drugs in non-human primates. Assessment of brain exposure and dose dependent effects on brain exposure using positron emission tomography (2012) (0)
Stabilizing the dopamine-serotonin system: a new goal in the management of schizophrenia (2002) (0)
Two new halogenated analogues of WAY-100635 as potential PET radioligands for the study of 5-HT1A receptors. (2000) (0)
PET D1-Receptor Studies in Schizophrenia (1996) (0)
Pet-Studies Using 11C-TZTP Derivatives for the Visualization of Muscarinic Receptors in the Human Brain (1997) (0)
Regional distribution of high and low affinity states of dopamine D2/3 receptor binding in humans: A PET study using [11C]MNPA and [11C]raclopride (2010) (0)
M7. LOWER THALAMIC DOPAMINE D2-RECEPTOR BINDING IN DRUG-NAIVE PATIENTS WITH PSYCHOSIS – A REPLICATION STUDY USING POSITRON EMISSION TOMOGRAPHY (2020) (0)
Effect of fenfluramine on 5-HT1B binding of [11C]AZ10419369 in the primate brain (2009) (0)
Low effect of amphetamine on the binding of the partial dopamine D-1 receptor agonist radioligand [C-11] N-methyl-NNC 01-0259 (2006) (0)
Serotonin transporter occupancy by escitalopram and citalopram in the non-human primate brain: a [11C]MADAM PET study (2015) (0)
S-18-2 Role of serotonin in psychosis (1995) (0)
Dr. Borg and Colleagues Reply (2004) (0)
Brain exposure of osimertinib in patients with EGFRm NSCLC and brain metastases: a PET and MRI study. (2023) (0)
PL01. 1 The interface between neuroscience and psychiatry (2000) (0)
P.3.004 Amphetamine-opioid interactions in the human brain reward system – a PET study using [11C]carfentanil (2012) (0)
Evaluation of two C-methyl derivatives of C-11-WAY-100635 as potential radioligands for 5-HT1A receptors. (2002) (0)
P.3.02 Molecular imaging of the 5-HT1A receptor and 5-HTT in relation to cognitive functions in man (2008) (0)
Is the 5-HT2-Receptor a Target for Antipsychotic Drug Action? PET Studies on Dopamine (D2 and Serotonin (5-HT2) Receptor Occupancy in Patients and Healthy Subjects (1995) (0)
Welcome and introduction (2002) (0)
Radiofarmaseutika of the preparations were radiojoderade bentsodiatsepinanaloger Science deras anvaendning i diaknostik (1996) (0)
Amyloid PET imaging using AZD4694 and unusually brief radiotracer uptake and scanning periods (2012) (0)
O-27-9 Reduced D1-dopamine receptor binding in schizophrenia — Relation to psychopathology (1996) (0)
Application of cross-species PET imaging to assess neurotransmitter release in brain (2015) (0)
Amyloid PET imaging using AZD4694 and unusually brief radiotracer uptake and scanning periods (2012) (0)
Modeling of PET data in CNS drug discovery and development (2013) (0)
Glia Imaging Shows Clinical Utility in Differentiating Parkinson's Disease from Multiple System Atrophy (2022) (0)
Effect of ligand mass dose on binding of the β-amyloid specific radioligand [18F]AZD4694 (NAV4694) (2013) (0)
Decrease of D1-dopamine receptor binding in the frontal cortex of neuroleptic naive schizophrenic patients measured by PET (1996) (0)
P.1.g.069 Relationship between dose, plasma concentration and GABA-A receptor occupancy by partial GABA-A receptor modulators (2015) (0)
Molecular Imaging (2020) (0)
The Central Role of Molecular Imaging in Clinical Neuroscience (2008) (0)
Dopamine transporter in the nigrostriatal system of adolescents with ADHD and neurocognitive performance (2003) (0)
The authors reply (1996) (0)
P.1.i.053 Associations between central chemokine levels and glial activation in first episode psychosis – a positron emission tomography study (2017) (0)
Abstract # 1847 Cross-sectional and longitudinal associations between immune cells in blood and brain – A TSPO PET study in healthy control subjects (2016) (0)
D1- and D2-dopamine receptor occupancy during treatment with classical and atypical neurpleptics (1990) (0)
P.1.e.030 In vivo monoamine transporter occupancy by venlafaxine and milnacipran in non-human primates (2011) (0)
O-27-5 Autoradiographic localization of 5-HT1A-receptors in the human brain (1996) (0)
GABA(A) Receptors in Autism - a Multicenter Positron Emission Tomography Study (2015) (0)
S-45-2 Distribution of dopamine receptor subtypes in the post-mortem human brain (1996) (0)
Beta-amyloid binding of [3]AZD4694 and [3H]AV45 in vitro (2011) (0)
Radioiodination of SB 207710 as a prospective radioligand for imaging 5-HT4 receptors in vivo-autoradiography of [125I] SB 207710 against human brain tissue (1999) (0)
The metabolite pattern of [123I]beta-CIT determined with a gradient HPLC method. (1995) (0)
Kinetic analysis of receptor binding with positron emission tomography. (1991) (0)
Automated system for parametric image analysis in neuroreceptor binding studies with PET (2008) (0)
Neuroimaging in Psychiatric Drug Development and Radioligand Development for New Targets (2020) (0)
The dopamine hypothesis of schizophrenia (2004) (0)
Common brain disorders are associated with heritable patterns of apparent aging of the brain (2019) (0)
European Association of Nuclear Medicine Congress 26–30 August 1995, Brussels, Belgium (2004) (0)
(18)F6FPWAY-synthesis and initial investigation as a prospective 5-HT1A receptor radioligand in vivo. (2001) (0)
Quantitative analysis of F-FE-PE2I binding to the dopamine transporter in Parkinson’s disease (2015) (0)
Dopamine transporter binding corrected for tissue heterogeneity and partial volume effect using [11C]PE2I and PET (2006) (0)
Proof of lung muscarinic receptor occupancy by tiotropium: Translational Positron Emission Tomography studies in non-human primates and humans (2023) (0)
D2 and 5-HT2 receptor occupancy in antipsychotic drug treated patients (1994) (0)
The Future of Psychopharmacology and Positron Emission Tomography (1990) (0)
Amyloid PET imaging using AZD4694 and unusually brief radiotracer uptake and scanning periods (2012) (0)
Increasing the accuracy of in vivo quantification of dopamine-D2/D3 receptor binding in the human brain by partial volume effect correction (2006) (0)
[C]PBB3 binding in Aβ(-) or Aβ(+) Corticobasal syndrome. (2023) (0)
PET Studies of Patients Treated with Antipsychotic Drugs (1989) (0)
D2-density, personality traits, and negative symptoms of schizophrenia (1998) (0)
PET evaluation of the dopamine D2 receptor agonist (2004) (0)
Optimal acquisition time window for quantification of dopamine transporter availability with [18F]FE-PE2I in controls and PD patients (2015) (0)
Useful in the radiopharmaceutical in the radioiodinated benzodiazepine derivatives and their use in the diagnosis (1996) (0)
A new quantitative approach for dopamine transporter binding using [11C]PE2I and PET allowing BBB-penetrating radiolabeled metabolite (2011) (0)
P-13-2 In vivo examination of the Pre- and postsynaptic dopamine neurons in huntington's disease (1996) (0)
P.1.j.040 Social cognition in autism spectrum disorder is associated with brain serotonin transporter availability (2017) (0)
SERT and NET occupancy by venlafaxine and milnacipran in nonhuman primates: a PET study (2012) (0)
The characteristics of the relationships between D2 receptor occupancy, antipsychotic effect and plasma prolactin (1999) (0)
11 Early clinical development of amyloid-beta specific PET radioligand [18F]AZD4694 (2012) (0)
[I-123]SB 207710 exhibits 5-HT4 receptor-selective binding in monkey brain in vivo. (2000) (0)
Dopamine Receptors and Neurological Side Effects (1996) (0)
16-4 PET studies of serotonergic mechanisms in the treatment of schizophrenia (1997) (0)
Glutamate 5 receptor availability differences in twins discordant for autism and controls, do shared genetics matter (2023) (0)
S.06.03 Is dopamine a variable in PET-studies on drug induced receptor occupancy? (2003) (0)
Two new C-methyl analogues of WAY-100635-preparation, labeling with carbon-11 and evaluation as PET radioligands for brain 5-HT1A receptors in monkey (2002) (0)
Abstract 2641: AZD4635 A2Areceptor occupancy in cynomolgus monkey using PET and its application to an oncology clinical development program (2017) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Lars Farde?

Lars Farde is affiliated with the following schools:

Karolinska Institute

Lars Farde's Academic­Influence.com Rankings

Why Is Lars Farde Influential?

Lars Farde's Published Works

Published Works

What Schools Are Affiliated With Lars Farde?

Lars Farde's AcademicInfluence.com Rankings